Highlights of This Issue 3089

SPECIAL FEATURES

3091 How to Train Your Biomarker
Douglas Yee
See article p. 3193

Inhibition of the PI3K Pathway: Hope We Can Believe in?
Michiel S. van der Heijden and René Bernards

Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Laurence Zitvogel, Oliver Kepp, Laura Senovilla, Laurie Menger, Nathalie Chaput, and Guido Kroemer

CCR Translations

3100 Drugs That Target the Stemness Pathways
Susan E. Bates

3104 Controversies in Cancer Stem Cells: Targeting Embryonic Signaling Pathways
Naoko Takebe and S. Percy Ivy

3110 Cancer Stem Cells and Self-renewal
Catherine Adell O’Brien, Antonija Kreso, and Catriona H.M. Jamieson

3117 The Difficulty of Targeting Cancer Stem Cell Niches
Mark A. LaBarge

3119 Targeting Hedgehog—a Cancer Stem Cell Pathway
Akil A. Merchant and William Matsui

3142 Targeting Notch to Target Cancer Stem Cells
Antonio Pannuti, Kimberly Foreman, Paola Rizzo, Clodia Osipo, Todd Golde, Barbara Osborne, and Lucio Miele

The Journal of Clinical and Translational Research

June 15, 2010 • Volume 16 • Number 12

Contents

3153 Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?
Fumi Takahashi-Yanaga and Michael Kahn

HUMAN CANCER BIOLOGY

3163 Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis
Akihiko Kawahara, Chizuko Yamamoto, Kazutaka Nakashima, Koichi Azuma, Satoshi Hattori, Masaki Kashihara, Hisamichi Aizawa, Yuji Basaki, Michihiko Kuwano, Masayoshi Kage, Tetsuya Mitsudomi, and Mayumi Ono

3171 Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2
Gong Yang, Bin Chang, Fan Yang, Xiaqing Guo, Kathy Qi Cai, Xue (Sherry) Xiao, Huaimin Wang, Subrata Sen, Mien-Chie Hung, Gordon B. Mills, Sandy Chang, Asha S. Multani, Imelda Mercado-Uribe, and Jinsong Liu

CANCER THERAPY: PRECLINICAL

3182 FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma
Qing Liu, Lapo Alinari, Ching-Shih Chen, Fengting Yan, James T. Dalton, Rosa Lapalombella, Xiaoli Zhang, Rajeswaran Mani, Teresa Lin, John C. Byrd, Robert A. Baiocchi, and Natarajan Muthusamy

3193 Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
Todd M. Pitts, Aik Choon Tan, Gillian N. Kulikowski, John J. Tentler, Amy M. Brown, Sara A. Flanigan, Stephen Leong, Christopher D. Coldren, Fred R. Hirsch, Marieleile Varella-Garcia, Christopher Korch, and S. Gail Eckhardt
See commentary p. 3091

See commentary p. 3091
CANCER THERAPY: CLINICAL

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
María Victoria Mateos, María Teresa Cibeira, Paul G. Richardson, Felipe Prosper, Albert Oriol, Javier de la Rubia, Juan José Lahuerta, Ramón García-Sanz, Sonia Extremera, Sergio Szyldergemajn, Claudia Corrado, Harald Singer, Constantine S. Mitsiades, Kenneth C. Anderson, Joan Bladé, and Jesús San Miguel

Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants
Barbara L. Andersen, Lisa M. Thornton, Charles L. Shapiro, William B. Farrar, Bethany L. Mundy, Hae-Chung Yang, and William E. Carson III

AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trail
Per-Uno Malmström, Angelica S.I. Loskog, Camilla A. Lindqvist, Sara M. Mangsbo, Moa Fransson, Alkwin Wanders, Truls Gårdmark, and Thomas H. Tötterman

Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients
ABOUT THE COVER

Early detection of gastric cancer requires risk assessment of premalignant conditions. The cover image shows a positive and negative representative immunostain of eight tissue markers (BRCA1, HSP90, EGFR, p73, STAT1, FHIT, p16INK4a and p53) and EBER-1 expression in tissue microarrays of early gastric cancer, nontumor adjacent mucosa, and chronic gastritis control cases, where p73 emerges and may have a potential role in the assessment of high-risk gastritis. Moreover, integration of these findings with histological features shows that overexpression of p73 is the most relevant finding. For further details, please see the article by Carrasco and colleagues on page 3253 of this issue.
Clinical Cancer Research

16 (12)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.